SEC Tracker
Get the app

Liminatus Pharma LIMN

Liminatus Pharma FY 2025: net loss $10.2M; diluted EPS −$0.43

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Liminatus Pharma reported for the year ended Dec 31, 2025, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$10.2MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Diluted EPS−$0.43No year-earlier figure tagged10-K income statement, on EDGAR
  3. Cash and cash equivalents$338KNo year-earlier figure tagged10-K balance sheet, on EDGAR
  4. Cash from operations−$10.0MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Liminatus Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Precigen PGEN public float $219M, Jun 30, 2025
  2. SELLAS Life Sciences Group SLS public float $219M, Jun 30, 2025
  3. Lifecore Biomedical LFCR public float $223M, Jun 30, 2025
  4. Sagimet Biosciences SGMT public float $228M, Jun 30, 2025
  5. Perspective Therapeutics CATX public float $213M, Jun 30, 2025